openPR Logo
Press release

Advanced Hepatocellular Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

10-25-2024 01:26 AM CET | Health & Medicine

Press release from: ABNewswire

Advanced Hepatocellular Carcinoma Pipeline Therapeutics,

DelveInsight's, "Advanced Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Hepatocellular Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

* In October 2024:- AstraZeneca- A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA). This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
* In October 2024:- Suzhou Suncadia Biopharmaceuticals Co., Ltd.- A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma.
* In October 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma. The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
* In October 2024:- Bristol-Myers Squibb- The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.
* In October 2024:- Replimune Inc.- A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma. The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
* In October 2024:- Coherus Biosciences Inc.- This is a Phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
* In October 2024:- AbbVie- A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment.
* In October 2024:- SOTIO Biotech AG- A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors. The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
* DelveInsight's Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
* The leading Advanced Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
* Promising Advanced Hepatocellular Carcinoma Therapies such as Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafeni b, and others.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Hepatocellular Carcinoma Emerging Drugs

* Tivozanib : AVEO Oncology

FOTIVDA Registered (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

* Nofazinlimab: CStone Pharmaceuticals

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.

* ECT 204: Eureka Therapeutics

ECT204, a GPC3 targeting ARTEMIS Registered T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

* Sintilimab: Eli Lilly and Company/Innovent

Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT Registered (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Hepatocellular Carcinoma Companies

CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.

Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Advanced Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

* Coverage- Global
* Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
* Advanced Hepatocellular Carcinoma Therapies- Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.
* Advanced Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Hepatocellular Carcinoma Pipeline on our website @ Advanced Hepatocellular Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced Hepatocellular Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase III)
* Nofazinlimab: CStone Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* Tivozanib : AVEO Oncology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Hepatocellular Carcinoma Key Companies
* Advanced Hepatocellular Carcinoma Key Products
* Advanced Hepatocellular Carcinoma - Unmet Needs
* Advanced Hepatocellular Carcinoma - Market Drivers and Barriers
* Advanced Hepatocellular Carcinoma - Future Perspectives and Conclusion
* Advanced Hepatocellular Carcinoma Analyst Views
* Advanced Hepatocellular Carcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-hepatocellular-carcinoma-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advanced Hepatocellular Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here

News-ID: 3709261 • Views:

More Releases from ABNewswire

Apps4.Pro Migration Manager Transforms Microsoft 365 Tenant Migration: Zero Data Loss, Maximum Speed, Enterprise Peace of Mind
Apps4.Pro Migration Manager Transforms Microsoft 365 Tenant Migration: Zero Data …
Tirunelveli, India - 30 August, 2025 - When global enterprises need to migrate their Microsoft 365 environments, failure isn't an option. A single misstep can mean lost data, broken workflows, and frustrated teams. Today, Apps4.Pro-trusted by over 15,000 organizations worldwide-announces the enhanced Migration Manager platform that's redefining what's possible in tenant-to-tenant migration. From Fortune 500 giants like Siemens Energy and Johnson & Johnson to fast-scaling startups, organizations are discovering a migration
Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs Increase Insurance Risks
Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs I …
Brandon, FL - Homeowners in Brandon, Florida, are facing increased pressure to replace aging roofs as insurance companies tighten coverage requirements. Dynamic Roofing Concepts provides roof replacement in Brandon, FL [https://www.dynamicroofingconcepts.com/] and has seen increased demand as local homeowners face pressure from insurance companies to replace aging roofs. In Florida, most homeowners are aware that old roofs are more vulnerable to wind and water damage. Insurance providers have responded by requiring
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert Guide for Austin, TX
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert G …
Not sure when to contact an exterminator? Evo Foam Pest Control explains the common signs of pest problems in Austin and why timely intervention is essential. Austin, TX - Pest infestations can occur at any time, leaving homeowners in Austin, TX, wondering when it's necessary to call an exterminator Austin TX. With numerous pests, including ants, rodents, and termites, threatening the comfort of homes, it's essential to recognize the signs that
Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Homes Safe and Healthy
Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Ho …
Discover how Palm Coast Pest Control uses eco-friendly solutions to protect Jupiter, FL homes from pests while maintaining a healthy, chemical-free environment. Jupiter, FL - As residents of Jupiter, FL, seek effective and sustainable solutions to pest problems, Palm Coast Pest Control stands out as a trusted provider of eco-friendly pest control services. The company has earned a reputation for its commitment to keeping homes safe, healthy, and pest-free while also

All 5 Releases


More Releases for Advanced

Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market. The
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits. Get Skincell Advanced From Its
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market: Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025. Overview of the Advanced Oxidation Technologies Market Report: Advanced Oxidation Technologies Market report includes knowledge about the market overview
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The